57988-60-0

Basic information

• Product Name: 4-(p-tolyl)piperidin-4-ol
• Synonyms: Einecs 261-066-6;4-(4-methylphenyl)piperidin-4-ol(SALTDATA: FREE);4-(4-methylphenyl)-4-piperidinol;4-Hydroxy-4-(4-methylphenyl)piperidine HCl
• CAS NO: 57988-60-0
• Molecular Formula: C₁₂H₁₇NO
• Molecular Weight: 191.28
• EINECS: 261-066-6
• Mol File: 57988-60-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 335.7°Cat760mmHg
• Flash Point: 133.9°C
• Appearance: /
• Density: 1.072g/cm³
• Vapor Pressure: 4.62E-05mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: 4-(p-tolyl)piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(p-tolyl)piperidin-4-ol(57988-60-0)
• EPA Substance Registry System: 4-(p-tolyl)piperidin-4-ol(57988-60-0)

Safety Data

• Hazardous Substances Data: 57988-60-0(Hazardous Substances Data)

Usage

General Description

4-(p-tolyl)piperidin-4-ol, also known as PTPO, is an organic compound with the molecular formula C13H19NO. It belongs to the piperidine class of chemicals and is a close analogue of piperidine. PTPO is a versatile chemical that can be used in the synthesis of various pharmaceuticals and organic compounds due to its unique structure and reactivity. It has been studied for its potential as a building block in the development of new drugs and as a key intermediate in the production of complex organic molecules. PTPO is known for its potential as a building block in the development of new drugs and as a key intermediate in the production of complex organic molecules. It is also used in research laboratories as a reagent for various chemical reactions and processes.

InChI:InChI=1/C12H17NO/c1-10-2-4-11(5-3-10)12(14)6-8-13-9-7-12/h2-5,13-14H,6-9H2,1H3

Upstream product

• 13299-35-9 1-benzyl-4-(4-methylphenyl)piperidin-4-ol 
• 7440-05-3 palladium 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 106-38-7 para-bromotoluene 
• 1260882-14-1 tert-butyl 4-hydroxy-4-(p-tolyl)piperidine-1-carboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 91801-93-3 4-Bromo-4-p-tolyl-piperidine 

Downstream Products

• 1050-79-9 moperone 
• 59995-69-6 4-(4-hydroxy-4-p-tolyl-piperidino)-1-phenyl-butan-1-one 
• 1027520-31-5 2-(4-Hydroxy-4-p-tolyl-piperidin-1-yl)-1-(4-triisopropylsilanyloxy-phenyl)-propan-1-one 
• 14862-80-7 4-(4-hydroxy-4-phenylpiperidin-1-yl)-1-phenylbutan-1-one 
• 200050-87-9 (+)-6-(3,4-Difluorophenyl)-1,6-dihydro-5-methoxycarbonyl-2,4-dimethyl-1-(4(S)-methyl-5-(4-(2-methylphenyl)-4-(4-methyl-phenyl)piperidin-1-yl)pentyl)pyrimidine 
• 200052-37-5 1-(3-amino-propyl)-4-(4-methyl)-phenyl-4-(2-methyl)-phenyl-piperidine 
• 13299-35-9 1-benzyl-4-(4-methylphenyl)piperidin-4-ol 

Relevant articles and documents

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

Studies on the N-dealkylated metabolite of haloperidol

The recent detection of 4-Chlorophenyl-4-piperidinol (CPPO), in rats fed haloperidol and the subsequent demonstration that CPPO produces a freezing action in frogs, has encouraged us to study the structural features that might be responsible for the freezing action. In this study, we have shown that removal of the chloro from the phenyl ring has little effect on the freezing action and the removal of the tertiary alcohol from the piperidine only decreases somewhat the effectiveness of the freezing action. In addition, since replacing the piperidine ring with tetrahydropyridine and piperazine moieties led to compounds without the freezing action, and because 4-phenylpiperidine is the common entity in all the compounds with the freezing action, it is reasonable to suggest that the 4-phenylpiperidine moiety may be responsible for the freezing action observed in CPPO.